CIK 0001819411
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
Gain Therapeutics, Inc.
Sign in to watch- Ticker
- GANX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 851726310
- Phone
- +1 301-500-1556
- Business address
- 4800 HAMPDEN LANE, SUITE 200, BETHESDA, MD, 20814
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Derivatives Options or other derivatives
- 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 2,482 shares at $2.58 ($6,404)
- 4 Open-market buy CHIEF EXECUTIVE OFFICER bought 13,256 shares at an average $2.79 ($37,034)
- 4/A Open-market buy CHIEF FINANCIAL OFFICER bought 3,000 shares at $2.70 ($8,100)
- 4 Open-market buy CHIEF FINANCIAL OFFICER bought 3,000 shares at $8,100.00 ($24,300,000)
- 4/A Open-market buy Chief Executive Officer bought 4,922 shares at $7.87 ($38,716)
- 3/A Insider 3/A
- 4 Derivatives Options or other derivatives
- 3 Insider Initial Statement of Ownership
- 4 Exercise or conversion Director acquired 4,922 shares (option exercise)
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
- 3 Insider Initial Statement of Ownership
Page 4 of 5 · 82 filings